UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 5, 2006
NEOSTEM, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-10909 22-2343568
-------- ------- ----------
(State Or Other (Commission (IRS Employer
Jurisdiction Of File Number) Identification No.)
Incorporation)
420 Lexington Avenue, Suite 450
New York, New York 10170
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212)-584-4180
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
NeoStem, Inc. (the "Company") expects to operate at break even on a cash flow
basis at such time as it is collecting from clients approximately 360 adult stem
cell specimens per month and it has in storage approximately 2,000 adult stem
cell specimens. Be cautioned that this is a forward looking statement which the
Company believes is reasonable at this time, but it is subject to a number of
contingencies and assumptions which may not be realized.
Item 8.01. Other Events.
On December 5, 2006, the Compensation Committee of the Board of Directors
approved awards to management and senior staff under the Company's 2003 Equity
Participation Plan (the "EPP") as follows: (i) options to purchase an aggregate
of 1,225,000 shares of common stock, $.001 par value (the "Common Stock") at a
per share purchase price equal to $.60, the closing price of the Common Stock on
the date of grant, of which 150,000 were fully vested upon grant and 1,075,000
vest upon the achievement of specified milestones; and (ii) an aggregate of
500,000 shares of Common Stock of which 200,000 were fully vested on the date of
grant and 300,000 vest upon the achievement of specified milestones.
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NEOSTEM, INC.
By: /s/ Catherine M. Vaczy
----------------------
Catherine M. Vaczy
Vice President and General Counsel
Dated: December 11, 2006